Whole-cell vaccination, a promising strategy in immunotherapy, provides multiple identified and unidentified tumor-associated antigens (TAAs) that activate CD4+ and CD8+ CTLs, thereby minimizing immune escape [17]. The gene discussed is CD8A; the disease is neoplasm.